Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer

  • Technology appraisal guidance
  • TA310
  • Published: 
Download guidance (PDF)

1 Guidance

1.1 Afatinib is recommended as an option, within its marketing authorisation, for treating adults with locally advanced or metastatic non-small-cell lung cancer only if:

  • the tumour tests positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and

  • the person has not previously had an EGFR-TK inhibitor and

  • the manufacturer provides afatinib with the discount agreed in the patient access scheme.